Related Experiment Video
Updated: Oct 24, 2025

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
The current landscape of lipoprotein(a) in calcific aortic valvular disease
Grace Hsieh1, Theresa Rizk2, Adam N Berman1
1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Insights
Lipoprotein (a) drives calcific aortic stenosis (CAVS) by carrying oxidized phospholipids, leading to inflammation and valve calcification. Therapies targeting lipoprotein (a) show promise for halting CAVS progression.
Area of Science:
- Cardiology
- Biochemistry
- Genetics
Background:
- Calcific aortic stenosis (CAVS) is a prevalent valvular heart disease in aging populations.
- Current treatments for severe aortic stenosis (AS) involve valve replacement.
- Lipoprotein (a) [Lp(a)] is increasingly recognized as a significant factor in CAVS.
Purpose of the Study:
- To review the pathophysiology of CAVS linked to Lp(a).
- To summarize emerging therapies targeting Lp(a) for CAVS.
- To explore Lp(a) as a therapeutic target for AS.
Main Methods:
- Review of recent pathophysiologic, epidemiological, and genetic studies.
- Analysis of Lp(a)'s role in valvular calcification.
- Evaluation of ongoing Lp(a)-lowering therapy studies.
Main Results:
- Lp(a) acts as a key carrier of pro-calcifying oxidized phospholipids (OxPL).
- OxPL metabolism promotes inflammation, valvular thickening, and mineralization.
- Lp(a) is identified as a causal mediator of calcific aortic valvular disease (CAVD).
Conclusions:
- Lp(a) plays a critical, rate-limiting role in CAVS progression.
- Lp(a)-lowering therapies offer potential novel pharmacotherapies for AS.
- Targeting Lp(a) may significantly impact the clinical management of CAVD.
Purpose Of Review:
Calcific aortic stenosis (CAVS) is the most common form of valvular heart disease in developed countries, increasing in prevalence with the aging population. Surgical or transcatheter aortic valve replacement is the only treatment available for CAVS. However, these interventions are typically reserved for severe symptomatic aortic stenosis (AS). The purpose of this review is to summarize the recent literature in uncovering the underlying pathophysiology of CAVS in the setting of lipoprotein (a) [Lp(a)] and emerging therapies targeting Lp(a) which may help halt disease progression in CAVS.
Recent Findings:
Pathophysiologic, epidemiological, and genetic studies over the past two decades have provided strong evidence that Lp(a) is an important mediator of calcific aortic valvular disease (CAVD). Studies suggest that Lp(a) is a key carrier of pro-calcifying oxidized phospholipids (OxPL). The metabolism of OxPL results in a pro-inflammatory state and subsequent valvular thickening and mineralization through pro-osteogenic signaling. The identification of Lp(a) as a causal mediator of CAVD has allowed for opportunities for emerging therapeutic agents which may slow the progression of CAVD (Fig. 1JOURNAL/cocar/04.03/00001573-202109000-00007/figure1/v/2021-08-04T080204Z/r/image-jpeg).
Summary:
This review summarizes the current knowledge on the association of Lp(a) with CAVD and ongoing studies of potential Lp(a)-lowering therapies. Based on the rate-limiting and causal role of Lp(a) in progression of CAVS, these therapies may represent novel pharmacotherapies in AS and inform the developing role of Lp(a) in the clinical management of CAVD.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Aortic Regurgitation III: Medical Management
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction
Aortic Regurgitation I: Introduction

